TQL1055 adjuvant based acellular pertussis vaccine / Adjuvance Tech - LARVOL DELTA

Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - P1 | N=72 | Terminated | Sponsor: Adjuvance Technologies, Inc. | Trial completion date: Sep 2022 ➔ Feb 2022 | Active, not recruiting ➔ Terminated; financial constraints

Trial completion date • Trial termination • Infectious Disease • Pertussis • Respiratory Diseases

Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant (Businesswire) - P1, N=72; NCT04793620; Sponsor: Adjuvance Technologies, Inc.; "Adjuvance Technologies Inc...announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine...Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine...Further data will be presented at IDWeek 2021."

P1 data • Infectious Disease • Pertussis

Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: Adjuvance Technologies, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2022 ➔ Sep 2022

Clinical • Enrollment closed • Trial completion date • Infectious Disease • Pertussis • Respiratory Diseases

Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Adjuvance Technologies, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Pertussis • Respiratory Diseases

Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Adjuvance Technologies, Inc.

Clinical • New P1 trial • Infectious Disease • Pertussis • Respiratory Diseases